Matthias Hebben
Chief Tech/Sci/R&D Officer bij LOGICBIO THERAPEUTICS, INC.
Profiel
Currently, Matthias Hebben is Vice President & Head-Technology Development at LogicBio Therapeutics, Inc.
In the past he held the position of Director-R&D Virology at Valneva SE and Director-AAV Technology & CMC Development at Généthon.
Dr. Hebben received a doctorate from the University of Nice Sophia Antipolis, an undergraduate degree from the University of Strasbourg and an undergraduate degree from Louis Pasteur University.
Actieve functies van Matthias Hebben
Bedrijven | Functie | Begin |
---|---|---|
LOGICBIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-02-2019 |
Eerdere bekende functies van Matthias Hebben
Bedrijven | Functie | Einde |
---|---|---|
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Corporate Officer/Principal | 01-02-2019 |
VALNEVA | Corporate Officer/Principal | 01-01-2013 |
Opleiding van Matthias Hebben
University of Strasbourg | Undergraduate Degree |
University of Nice Sophia Antipolis | Doctorate Degree |
Louis Pasteur University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
VALNEVA | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Health Technology |
LogicBio Therapeutics, Inc.
LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |